Johnson & Johnson (JNJ) Tops Q3 EPS by 3c, Revenues Beat; Maintains Outlook

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.55, $0.03 better than the analyst estimate of $2.52. Revenue for the quarter came in at $23.79 billion versus the consensus estimate of $23.46 billion.

GUIDANCE:

The company is maintaining 2022 full-year guidance midpoints for adjusted operational sales and reported adjusted EPS; increasing adjusted operational EPS performance offsetting continued unfavorable currency impact

The company sees FY Adjusted Operational Sales of $97.5-$98 billion, versus $97.3-$98.3 billion. Sees Adjusted Operational EPS of $10.70-$10.75, versus prior of $10.65-$10.75.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
• Biogen expects $164M R&D charge to hit Q2 2026 earnings